CDK9 and cancer: Importantly, we show that the sensitivity signature derived from genes highly expressed in TAK1-dependent cells can be used to predict sensitivity to TAK inhibition in cancer cells and might be used in the future to select patients benefitting from TAK1 targeted therapy.